At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).
Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).
French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Leiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors.
Oslo-based Lytix Biopharma has a new Chief Business Officer. Stephen Worsley has started at the Norwegian immune-oncology company at the beginning of September.
Finance Expert Pascal Bricout strengthens French Carbios as Chief of Strategy; Financial Officer and a member of the Executive Committee.
Schwan follows Franz, Schinecker follows Schwan.
Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as president of the company. She succeeds Greg Milosevich, who has left the company.
Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.